Developer docs
API playgroundTry for free, no card

Search company profiles

Pathway to Cures

Full company profile

uuid000cf4f

Namestring
Pathway to Cures
Legal namestring
Pathway to Cures
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund launched in September 2022 by the National Bleeding Disorders Foundation (NBDF, formerly National Hemophilia Foundation). The fund addresses an early-stage funding gap for biotech companies developing therapies for inheritable blood and bleeding disorders — a disease area affecting more than 20 million people globally — with particular focus on underserved conditions beyond hemophilia A and B, including von Willebrand disease, sickle cell disease, thalassemia, and rare factor deficiencies. P2C operates as an evergreen investment vehicle with an initial $3.5 million commitment from NBDF and a stated fundraising target of $20 million; minimum donor commitments are $500,000.

P2C's core activity is direct equity and partnership investment in early-stage biotech companies, with all realized investment returns reinvested back into the fund to compound mission impact. Its portfolio spans six companies and six therapeutic modalities: Anvesana (antisense oligonucleotides for hemophilia and Factor XI deficiency), Afimmune (Epeleuton small molecule for sickle cell disease and thalassemia), Be Biopharma (engineered B-cell medicines for hemophilia B, in Phase 1/2), Spark Biomedical / Five Liters (non-invasive vagus nerve stimulation for von Willebrand disease and heavy menstrual bleeding, with the OhmBody wellness brand), Seawolf Therapeutics (non-viral DNA delivery for hemophilia A and B), and SeraGene Therapeutics (RNA-based lipid nanoparticle therapies for coagulation disorders, headquartered in Vancouver). Investments are evaluated by an Investment Committee and a Scientific Advisory Group comprising world-renowned hematology and gene therapy experts.

P2C's go-to-market model leverages NBDF's 75-year legacy in bleeding disorders, including access to the Community Voices in Research patient registry, 50 U.S. chapters, and deep relationships with clinical experts at leading treatment centers (Yale, OHSU, University of Michigan, Nationwide Children's). The fund reaches donors, biotech partners, and the patient community through its website, LinkedIn, The Pathway Pulse newsletter, press releases, webinars, and industry conferences. P2C is headquartered at 1230 Avenue of the Americas, New York, NY, and operates with a lean team of 1–10 employees.

Short descriptiontext

Pathway to Cures is a nonprofit venture philanthropy fund that invests in early-stage biotech companies developing therapies for inheritable blood and bleeding disorders. Established in 2022 by the National Bleeding Disorders Foundation, the fund operates from New York with a $3.5M initial commitment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture philanthropy fund, biotech investment vehicle, blood disorder therapies, nonprofit investment fund, early-stage biotech funding
Industry3 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
NAICS code3 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services81321
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Social Services8300
Product category
Venture Philanthropy Fund
Social media profiles1 record
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund that invests philanthropic and investment capital in early-stage biotechnology companies developing transformational therapies and technologies for inheritable blood and bleeding disorders. The fund combines charitable donations (minimum $500,000) with venture-style equity investments in portfolio companies, reinvesting all returns back into the fund to amplify mission impact. It does not sell products or services directly; instead, it deploys capital, scientific advisory support, and access to NBDF's patient registry and clinical networks to portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation, not a product company. It does not sell products or services directly. Instead, it operates as an investment vehicle that funds biotech companies developing therapies for inheritable blood and bleeding disorders. The fund's portfolio includes investments in six biotech companies: Anvesana (ASO therapeutics for bleeding disorders), Afimmune (Epeleuton for sickle cell disease and thalassemia), Be Biopharma (engineered B-cell medicine for hemophilia B), Spark Biomedical/OhmBody (non-invasive wearable neurostimulation device for von Willebrand disease and heavy menstrual bleeding), Seawolf Therapeutics (non-viral DNA delivery platform for hemophilia A and B), and SeraGene Therapeutics (RNA-based therapies using lipid nanoparticles for von Willebrand disease with focus on women's health). The fund's role is investment and strategic guidance, not direct product provision.

Product and service2 records
1Pathway to Cures Venture Philanthropy Fund
CategoryVenture Philanthropy Investment
Description

An evergreen nonprofit venture philanthropy fund that provides early-stage equity investment, strategic guidance, and access to the National Bleeding Disorders Foundation's patient registry and scientific advisory network to biotech companies developing therapies for inheritable blood and bleeding disorders.

2Venture Philanthropy Donor Program
CategoryPhilanthropic Giving Program
Description

A donation program accepting transformational contributions (minimum $500,000) from individuals, groups, and institutions. Donations are deployed as mission-aligned investments in portfolio biotechs, with returns reinvested into the fund.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NBDF is the parent organization of Pathway to Cures. P2C is NBDF's venture philanthropy fund created to accelerate the development of cures across all inheritable blood and bleeding disorders. NBDF provides funding, patient registry access (Community Voices in Research), scientific community relationships, and advisory panel programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Feinstein Institutes at Northwell Health conducted over 20 years of research on vagus nerve stimulation and hemostasis that underlies Spark Biomedical's technology. Dr. Kevin Tracey is a co-author on key Nature Communications research demonstrating the mechanism of action.

3Oregon Health & Science University (OHSU)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

OHSU is a collaborating institution for the LUNA Trial evaluating transcutaneous auricular neurostimulation for heavy menstrual bleeding. Dr. Michael Recht previously served as Director of the Hemophilia Center at OHSU from 2007 until 2020.

pathwaytocures.org
Strategic tierMinorTypeStrategic or Co-development Partner
Description

University of Michigan is a collaborating institution for the LUNA Trial. Dr. Steven Pipe, a member of P2C's Scientific Advisory Group, is a Professor at the University of Michigan and Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Yale University is a collaborating institution for the LUNA Trial. Dr. Michael Recht serves as Professor of Clinical Pediatrics at Yale University School of Medicine and is P2C's Chief Medical and Scientific Advisor.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Portal Innovations is a laboratory incubator facility in Chicago's Fulton Market district (and Atlanta's Science Square) where P2C holds its fund update meetings and portfolio companies can access laboratory space.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Friedreich's Ataxia Research Alliance (FARA)
TypeDirect peer
Description

FARA funds biotech development for Friedreich's ataxia, a rare inherited disease, using venture philanthropy tactics including direct biotech investments. Comparable to P2C as a small rare-disease venture philanthropy organization.

TypeDirect peer
Description

ADDF is a venture philanthropy foundation funding early-stage Alzheimer's drug development with biotech-focused investments and scientific advisory networks. Comparable to P2C in structure (nonprofit biotech investor) and patient-mission orientation.

TypeDirect peer
Description

Venture philanthropy fund of JDRF (Juvenile Diabetes Research Foundation) investing in Type 1 diabetes therapeutics. Directly comparable to P2C as a disease-focused philanthropic venture fund leveraging a parent patient-advocacy organization and reinvesting returns.

TypeDirect peer
Description

The pioneering rare-disease venture philanthropy organization that funded development of Kalydeco, Trikafta, and other CFTR modulators. Directly comparable to P2C as a patient-founded venture philanthropy vehicle funding early-stage biotech for a single rare disease, with returns reinvested into mission.

TypeBroad incumbent
Description

Commercial rare-disease biopharmaceutical company that developed and commercialized Roctavian, the first approved AAV gene therapy for hemophilia A. Comparable to P2C as the strategic acquirer/integrator that venture philanthropy-backed hemophilia assets eventually flow toward.

TypeDirect peer
Description

MMRF's Myeloma Investment Fund is a venture philanthropy vehicle that has funded numerous myeloma therapies to approval. Directly comparable as a disease-specific venture philanthropy arm using donor capital to underwrite early-stage biotech.

TypeEmerging player
Description

CMTA funds research and biotech development for Charcot-Marie-Tooth disease, a rare inherited neurological disorder. Comparable to P2C as a smaller rare inherited disease venture philanthropy organization building a portfolio of therapeutic investments.

TypeEmerging player
Description

Childhood cancer research nonprofit that has expanded into biotech venture investments. Comparable to P2C as a smaller-scale philanthropic research investor in a specific disease area.

TypeDirect peer
Description

LLS's Therapy Acceleration Program invests philanthropic capital directly into biotech developing blood cancer therapies. Comparable to P2C as a venture philanthropy arm of a major blood-disease patient organization funding clinical-stage assets.

TypeEmerging player
Description

PPMD funds Duchenne muscular dystrophy research and has backed biotech programs. Comparable to P2C as a rare inherited disease venture philanthropy organization leveraging patient community expertise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pathway to Cures

Venture Philanthropy Fundpathwaytocures.org

Pathway to Cures is a nonprofit venture philanthropy fund that invests in early-stage biotech companies developing therapies for inheritable blood and bleeding disorders. Established in 2022 by the National Bleeding Disorders Foundation, the fund operates from New York with a $3.5M initial commitment.

What Pathway to Cures does

Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund launched in September 2022 by the National Bleeding Disorders Foundation (NBDF, formerly National Hemophilia Foundation). The fund addresses an early-stage funding gap for biotech companies developing therapies for inheritable blood and bleeding disorders — a disease area affecting more than 20 million people globally — with particular focus on underserved conditions beyond hemophilia A and B, including von Willebrand disease, sickle cell disease, thalassemia, and rare factor deficiencies. P2C operates as an evergreen investment vehicle with an initial $3.5 million commitment from NBDF and a stated fundraising target of $20 million; minimum donor commitments are $500,000.

P2C's core activity is direct equity and partnership investment in early-stage biotech companies, with all realized investment returns reinvested back into the fund to compound mission impact. Its portfolio spans six companies and six therapeutic modalities: Anvesana (antisense oligonucleotides for hemophilia and Factor XI deficiency), Afimmune (Epeleuton small molecule for sickle cell disease and thalassemia), Be Biopharma (engineered B-cell medicines for hemophilia B, in Phase 1/2), Spark Biomedical / Five Liters (non-invasive vagus nerve stimulation for von Willebrand disease and heavy menstrual bleeding, with the OhmBody wellness brand), Seawolf Therapeutics (non-viral DNA delivery for hemophilia A and B), and SeraGene Therapeutics (RNA-based lipid nanoparticle therapies for coagulation disorders, headquartered in Vancouver). Investments are evaluated by an Investment Committee and a Scientific Advisory Group comprising world-renowned hematology and gene therapy experts.

P2C's go-to-market model leverages NBDF's 75-year legacy in bleeding disorders, including access to the Community Voices in Research patient registry, 50 U.S. chapters, and deep relationships with clinical experts at leading treatment centers (Yale, OHSU, University of Michigan, Nationwide Children's). The fund reaches donors, biotech partners, and the patient community through its website, LinkedIn, The Pathway Pulse newsletter, press releases, webinars, and industry conferences. P2C is headquartered at 1230 Avenue of the Americas, New York, NY, and operates with a lean team of 1–10 employees.

Pathway to Cures firmographics

Firmographics
Name
Pathway to Cures
Legal name
Pathway to Cures
Website
https://pathwaytocures.org
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Pathway to Cures is a nonprofit venture philanthropy fund that invests in early-stage biotech companies developing therapies for inheritable blood and bleeding disorders. Established in 2022 by the National Bleeding Disorders Foundation, the fund operates from New York with a $3.5M initial commitment.
Ownership category
akta.pro rank

Pathway to Cures industry classification

Industry
Product category
Venture Philanthropy Fund
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)

Keywords

  • Venture philanthropy fund
  • Biotech investment vehicle
  • Blood disorder therapies
  • Nonprofit investment fund
  • Early-stage biotech funding

Where Pathway to Cures is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pathway to Cures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels7 records

Pathway to Cures product offering

Product offering

Core offering

Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund that invests philanthropic and investment capital in early-stage biotechnology companies developing transformational therapies and technologies for inheritable blood and bleeding disorders. The fund combines charitable donations (minimum $500,000) with venture-style equity investments in portfolio companies, reinvesting all returns back into the fund to amplify mission impact. It does not sell products or services directly; instead, it deploys capital, scientific advisory support, and access to NBDF's patient registry and clinical networks to portfolio companies.

Product overview

Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation, not a product company. It does not sell products or services directly. Instead, it operates as an investment vehicle that funds biotech companies developing therapies for inheritable blood and bleeding disorders. The fund's portfolio includes investments in six biotech companies: Anvesana (ASO therapeutics for bleeding disorders), Afimmune (Epeleuton for sickle cell disease and thalassemia), Be Biopharma (engineered B-cell medicine for hemophilia B), Spark Biomedical/OhmBody (non-invasive wearable neurostimulation device for von Willebrand disease and heavy menstrual bleeding), Seawolf Therapeutics (non-viral DNA delivery platform for hemophilia A and B), and SeraGene Therapeutics (RNA-based therapies using lipid nanoparticles for von Willebrand disease with focus on women's health). The fund's role is investment and strategic guidance, not direct product provision.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pathway to Cures Venture Philanthropy Fund An evergreen nonprofit venture philanthropy fund that provides early-stage equity investment, strategic guidance, and access to the National Bleeding Disorders Foundation's patient registry and scientific advisory network to biotech companies developing therapies for inheritable blood and bleeding disorders.
  • Venture Philanthropy Donor Program A donation program accepting transformational contributions (minimum $500,000) from individuals, groups, and institutions. Donations are deployed as mission-aligned investments in portfolio biotechs, with returns reinvested into the fund.

Companies that use Pathway to Cures

Customer profile

Segments3 records

Ideal customer profiles2 records

Pathway to Cures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Pathway to Cures partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • National Bleeding Disorders Foundation (NBDF)coreStrategic or Co-development PartnerNBDF is the parent organization of Pathway to Cures. P2C is NBDF's venture philanthropy fund created to accelerate the development of cures across all inheritable blood and bleeding disorders. NBDF provides funding, patient registry access (Community Voices in Research), scientific community relationships, and advisory panel programs.
  • Feinstein Institutes for Medical ResearchcoreStrategic or Co-development PartnerThe Feinstein Institutes at Northwell Health conducted over 20 years of research on vagus nerve stimulation and hemostasis that underlies Spark Biomedical's technology. Dr. Kevin Tracey is a co-author on key Nature Communications research demonstrating the mechanism of action.
  • Oregon Health & Science University (OHSU)minorStrategic or Co-development PartnerOHSU is a collaborating institution for the LUNA Trial evaluating transcutaneous auricular neurostimulation for heavy menstrual bleeding. Dr. Michael Recht previously served as Director of the Hemophilia Center at OHSU from 2007 until 2020.
  • University of MichiganminorStrategic or Co-development PartnerUniversity of Michigan is a collaborating institution for the LUNA Trial. Dr. Steven Pipe, a member of P2C's Scientific Advisory Group, is a Professor at the University of Michigan and Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program.
  • Yale UniversityminorStrategic or Co-development PartnerYale University is a collaborating institution for the LUNA Trial. Dr. Michael Recht serves as Professor of Clinical Pediatrics at Yale University School of Medicine and is P2C's Chief Medical and Scientific Advisor.
  • Portal InnovationsminorStrategic or Co-development PartnerPortal Innovations is a laboratory incubator facility in Chicago's Fulton Market district (and Atlanta's Science Square) where P2C holds its fund update meetings and portfolio companies can access laboratory space.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Pathway to Cures competitors and assessment

Company assessment

Direct peers

  • Friedreich's Ataxia Research Alliance (FARA): FARA funds biotech development for Friedreich's ataxia, a rare inherited disease, using venture philanthropy tactics including direct biotech investments. Comparable to P2C as a small rare-disease venture philanthropy organization.
  • Alzheimer's Drug Discovery Foundation: ADDF is a venture philanthropy foundation funding early-stage Alzheimer's drug development with biotech-focused investments and scientific advisory networks. Comparable to P2C in structure (nonprofit biotech investor) and patient-mission orientation.
  • JDRF T1D Fund: Venture philanthropy fund of JDRF (Juvenile Diabetes Research Foundation) investing in Type 1 diabetes therapeutics. Directly comparable to P2C as a disease-focused philanthropic venture fund leveraging a parent patient-advocacy organization and reinvesting returns.
  • Cystic Fibrosis Foundation: The pioneering rare-disease venture philanthropy organization that funded development of Kalydeco, Trikafta, and other CFTR modulators. Directly comparable to P2C as a patient-founded venture philanthropy vehicle funding early-stage biotech for a single rare disease, with returns reinvested into mission.
  • Multiple Myeloma Research Foundation (Myeloma Investment Fund): MMRF's Myeloma Investment Fund is a venture philanthropy vehicle that has funded numerous myeloma therapies to approval. Directly comparable as a disease-specific venture philanthropy arm using donor capital to underwrite early-stage biotech.
  • Leukemia & Lymphoma Society Therapy Acceleration Program: LLS's Therapy Acceleration Program invests philanthropic capital directly into biotech developing blood cancer therapies. Comparable to P2C as a venture philanthropy arm of a major blood-disease patient organization funding clinical-stage assets.

Broad incumbents

  • BioMarin Pharmaceutical: Commercial rare-disease biopharmaceutical company that developed and commercialized Roctavian, the first approved AAV gene therapy for hemophilia A. Comparable to P2C as the strategic acquirer/integrator that venture philanthropy-backed hemophilia assets eventually flow toward.

Emerging players

  • Charcot-Marie-Tooth Association (CMTA): CMTA funds research and biotech development for Charcot-Marie-Tooth disease, a rare inherited neurological disorder. Comparable to P2C as a smaller rare inherited disease venture philanthropy organization building a portfolio of therapeutic investments.
  • Alex's Lemonade Stand Foundation: Childhood cancer research nonprofit that has expanded into biotech venture investments. Comparable to P2C as a smaller-scale philanthropic research investor in a specific disease area.
  • Parent Project Muscular Dystrophy: PPMD funds Duchenne muscular dystrophy research and has backed biotech programs. Comparable to P2C as a rare inherited disease venture philanthropy organization leveraging patient community expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Pathway to Cures social profiles

Digital presence

Pathway to Cures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pathway to Cures leadership team

Management profile

Number of profiles

Profiles19 records

Pathway to Cures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pathway to Cures M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathway to Cures

What does Pathway to Cures do?

Pathway to Cures (P2C) is a 501(c)(3) nonprofit venture philanthropy fund that invests philanthropic and investment capital in early-stage biotechnology companies developing transformational therapies and technologies for inheritable blood and bleeding disorders. The fund combines charitable donations (minimum $500,000) with venture-style equity investments in portfolio companies, reinvesting all returns back into the fund to amplify mission impact. It does not sell products or services directly; instead, it deploys capital, scientific advisory support, and access to NBDF's patient registry and clinical networks to portfolio companies.

Is Pathway to Cures a public or private company?

Pathway to Cures is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Pathway to Cures founded?

Pathway to Cures was founded in 2022. It employs 1 to 10 people.

Where is Pathway to Cures based?

Pathway to Cures is headquartered in New York, United States, in the North America region.

Who are Pathway to Cures's main competitors?

Direct peers on record are Friedreich's Ataxia Research Alliance (FARA), Alzheimer's Drug Discovery Foundation, JDRF T1D Fund, Cystic Fibrosis Foundation, Multiple Myeloma Research Foundation (Myeloma Investment Fund) and Leukemia & Lymphoma Society Therapy Acceleration Program. BioMarin Pharmaceutical is listed as a broad incumbent. Emerging players are Charcot-Marie-Tooth Association (CMTA), Alex's Lemonade Stand Foundation and Parent Project Muscular Dystrophy.

Does Pathway to Cures have an API?

No public API is recorded for Pathway to Cures.

What industry is Pathway to Cures in?

Pathway to Cures's product category is Venture Philanthropy Fund. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comNBDF’s Pathway to Cures Announces Spark Biomedical’s LUNA Trial to Advance Non-Pharmaceutical Options for Heavy Menstrual BleedingSpark Biomedical, a portfolio company of Pathway to Cures, has launched the LUNA Trial, a Phase II decentralized clinical study evaluating transcutaneous auricular neurostimulation (tAN) as a non-pharmaceutical treatment for heavy menstrual bleeding in women and girls with inherited bleeding disorders. The randomized, double-blind, sham-controlled study will enroll 80 participants in the United States, including adolescents ages 14–21 and adults ages 22–45 diagnosed with conditions such as von Willebrand disease. The trial is funded by Wellcome Leap and conducted in collaboration with Oregon Health & Science University, the University of Michigan, and Yale University.MorningstarNBDF’s Pathway to Cures Announces Spark Biomedical’s LUNA Trial to Advance Non-Pharmaceutical Options for Heavy Menstrual BleedingSpark Biomedical, a portfolio company of Pathway to Cures (NBDF's venture philanthropy fund), has announced the LUNA Trial, a Phase II decentralized clinical study evaluating transcutaneous auricular neurostimulation (tAN) as a drug-free treatment for heavy menstrual bleeding in women and girls with inherited bleeding disorders, including von Willebrand disease. The randomized, double-blind, sham-controlled study will enroll 80 participants ages 14-45 across the United States, with collaborating institutions including Oregon Health & Science University, the University of Michigan, and Yale University. The trial is funded by Wellcome Leap's The Missed Vital Sign program and aims to generate clinical evidence supporting non-pharmaceutical approaches to address a symptom that causes 46% of women with bleeding disorders to miss school or work.Pulse 2.0Pathway To Cures Invests In SeraGene Therapeutics To Advance RNA And Nanomedicine Treatments For Blood DisordersPathway to Cures, the National Bleeding Disorders Foundation's venture philanthropy fund, invested in SeraGene Therapeutics, a biotech developing RNA and nanomedicine therapies for blood coagulation disorders. The company's RNA therapies target liver cells to suppress plasminogen or boost coagulation genes, aiming to reduce dosing frequency. The investment adds to support from early backers including Hextwo Capital and Adage Capital Partners.Pulse 2.0SeraGene Therapeutics: Strategic Investment Raised From Pathway To Cures To Advance RNA-Based Treatments For Coagulation DisordersPathway to Cures, a venture philanthropy fund, invested in SeraGene Therapeutics, a biotech developing RNA-based treatments for coagulation disorders. The company's therapies use lipid nanoparticles to target liver cells, aiming to stabilize clots or boost coagulation genes. The investment supports SeraGene's work on inherited bleeding conditions, including von Willebrand disease.FinSMEsSeraGene Therapeutics Receives Investment from Pathway to CuresSeraGene Therapeutics, a Vancouver-based biotech developing clot-modifying siRNA therapies, received an undisclosed investment from Pathway to Cures. The company plans to use the funds to expand operations and R&D. The investment came from multiple early investors, including Hextwo Capital and others.citybizPathway to Cures Invests in SeraGene TherapeuticsPathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, has announced an investment in SeraGene Therapeutics, a preclinical biotech company developing proprietary RNA-based therapeutics for blood coagulation disorders. SeraGene, which spun out from the Versiti Blood Research Institute in Wisconsin and the Center for Blood Research at the University of British Columbia in Vancouver, leverages lipid nanoparticle technology to deliver siRNA therapies targeting the fibrinolytic pathway for improved clot stability. The investment is specifically aimed at advancing treatments for bleeding disorders including von Willebrand disease, with a focus on women's and girls' health.Business Wire BlogCORRECTING and REPLACING Pathway to Cures Invests in SeraGene TherapeuticsPathway to Cures, the venture philanthropy fund of the National Bleeding Disorders Foundation, announced an investment in SeraGene Therapeutics, a preclinical biotechnology company developing RNA-based therapies for blood coagulation disorders. SeraGene, based in Vancouver, Canada, uses proprietary siRNA technology delivered via lipid nanoparticles to target the fibrinolytic pathway, aiming to create long-acting prophylactic treatments for rare and common coagulation disorders. The investment, which joins Hextwo Capital as an early investor, will support the company's pipeline addressing conditions including von Willebrand disease with a focus on women's health.Business Wire BlogPathway to Cures Announces Venture Investment in Five LitersPathway to Cures invested $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop non-invasive therapies for inheritable blood and bleeding disorders. The company will conduct first-in-human studies on vagus nerve stimulation to reduce blood loss, targeting von Willebrand Disease, which affects 0.6-1.3% of the global population.